Amylyx Pharmaceuticals, Inc. AMLX
Institutional shares held
44.4 Million
235K
calls
530K
puts
Total value of holdings
$232M
$1.23M
calls
$2.77M
puts
Market Cap
$306M
58,533,200
Shares Out.
Institutional ownership
75.77%
# of Institutions
127
We take great care to ensure that the data presented and summarized in this overview for Amylyx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMLX
View all-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$24.2 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$16.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$11.1 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$10.6 Million0.04% of portfolio
-
683 Capital Management, LLC New York, NY2MShares$10.4 Million0.59% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.99MShares$10.4 Million3.01% of portfolio
-
Abrdn PLC1.97MShares$10.3 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.9MShares$9.92 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.77MShares$9.24 Million0.02% of portfolio
Latest Institutional Activity in AMLX
Top Purchases
Top Sells
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AMLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,690
+1.96%
|
$63,690
$1.57 P/Share
|
|
Sep 30
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,442
-7.37%
|
$34,326
$3.2 P/Share
|
|
Sep 30
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.57%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.59%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,709
-5.75%
|
$26,127
$3.2 P/Share
|
|
Sep 23
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,857
+0.06%
|
$1,857
$1.57 P/Share
|
|
Sep 12
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,449
+1.05%
|
$34,449
$1.57 P/Share
|
|
Sep 12
2024
|
James M Frates Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+14.63%
|
$80,000
$2.53 P/Share
|
|
Sep 05
2024
|
Karen Firestone |
BUY
Open market or private purchase
|
Direct |
50,000
+47.62%
|
$100,000
$2.13 P/Share
|
|
Sep 03
2024
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
100,000
+10.43%
|
$200,000
$2.2 P/Share
|
|
May 15
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,455
-6.46%
|
$10,455
$1.88 P/Share
|
|
May 15
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,250
+31.03%
|
$2,250
$1.89 P/Share
|
|
May 14
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,750
+50.0%
|
$2,750
$1.88 P/Share
|
|
Apr 16
2024
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,910
+38.43%
|
-
|
|
Apr 16
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.42%
|
-
|
|
Apr 16
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,560
+33.22%
|
-
|
|
Apr 16
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.32%
|
-
|
|
Apr 16
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,180
+28.75%
|
-
|
|
Mar 05
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,540
-1.86%
|
$27,720
$18.73 P/Share
|
|
Mar 05
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,792
-1.31%
|
$32,256
$18.73 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.34M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 1.02M shares |
|---|---|
| Open market or private purchase | 199K shares |
| Exercise of conversion of derivative security | 125K shares |
Sell / Disposition
203K
Shares
From
7
Insiders
| Open market or private sale | 99.4K shares |
|---|---|
| Bona fide gift | 103K shares |